Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
2001 1
2003 1
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Circulating monocyte subsets in human chronic graft-versus-host disease.
Konuma T, Kohara C, Watanabe E, Mizukami M, Nagai E, Oiwa-Monna M, Tanoue S, Isobe M, Jimbo K, Kato S, Takahashi S, Tojo A. Konuma T, et al. Bone Marrow Transplant. 2018 Dec;53(12):1532-1540. doi: 10.1038/s41409-018-0187-4. Epub 2018 May 4. Bone Marrow Transplant. 2018. PMID: 29728699
Chronic graft-versus-host disease (cGVHD) is a major cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). ...Alterations of surface markers in each circulating monocyte subset may
Chronic graft-versus-host disease (cGVHD) is a major cause of late morbidity and mortality after allogene
Cellular interactions in marrow-grafted patients. II. Normal monocyte antigen-presenting and defective T-cell-proliferative functions early after grafting and during chronic graft-versus-host disease.
Tsoi MS, Dobbs S, Brkic S, Ramberg R, Thomas ED, Storb R. Tsoi MS, et al. Transplantation. 1984 Jun;37(6):556-61. Transplantation. 1984. PMID: 6233768
Compared with cells from healthy marrow donors, T cell proliferation was found to be deficient in all recipients studied 36-71 days after grafting, regardless of the presence or absence of acute graft-versus-host disease and in most patients with ch
Compared with cells from healthy marrow donors, T cell proliferation was found to be deficient in all recipients studied 36-71 days after gr …
Blood versus marrow hematopoietic allogeneic graft.
Robinet E, Lapierre V, Tayebi H, Kuentz M, Blaise D, Tiberghien P. Robinet E, et al. Transfus Apher Sci. 2003 Aug;29(1):53-9. doi: 10.1016/S1473-0502(03)00104-6. Transfus Apher Sci. 2003. PMID: 12877895 Clinical Trial.
In addition, immune reconstitution and overall alloreactivity after BCT versus BMT differ significantly. Indeed, despite an increased number of donor T cells infused, the incidence of acute graft-versus-host disease (GvHD) after BCT appears to r …
In addition, immune reconstitution and overall alloreactivity after BCT versus BMT differ significantly. Indeed, despite an increased …
Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.
Storek J, Joseph A, Espino G, Dawson MA, Douek DC, Sullivan KM, Flowers ME, Martin P, Mathioudakis G, Nash RA, Storb R, Appelbaum FR, Maloney DG. Storek J, et al. Blood. 2001 Dec 15;98(13):3505-12. doi: 10.1182/blood.v98.13.3505. Blood. 2001. PMID: 11739150
The counts of circulating monocytes, natural killer cells, B cells, CD4 T cells, and CD8 T cells in the patients were not lower than in the donors. ...In contrast, the counts of TREC(+) CD4 T cells were lower in transplant recipients age 18 years or older, even in t …
The counts of circulating monocytes, natural killer cells, B cells, CD4 T cells, and CD8 T cells in the patients were not lowe …
Feedback